QBW251

Phase 2Small molecule

Novartis

QBW251 is one of 88 small molecule programs targeting Bronchiectasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiectasisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Cystic FibrosisActive, not recruiting

BronchiectasisPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Cystic FibrosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

26 2

Flovent

GSK

Preclinical

6 3

Spiriva

Boehringer Ingelheim

Preclinical

15 4

QBW251

Novartis

Phase 2

1 5

Duragesic

CCephalon

Preclinical

2 6

Narcan

SScienture

Preclinical

1 7

Zoloft

VViatris Specialty LLC

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

—9

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Iloprost Inhalation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

Completed· Novartis logo

Novartis·Phase 2·NCT04072887·974 enrolled

Bronchiectasis1 trial

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

Terminated· Novartis logo

Novartis·Phase 2·NCT04396366·42 enrolled

Cystic Fibrosis1 trial

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

Terminated· Novartis logo

Novartis·Phase 1/2·NCT02190604·153 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Terminated· Novartis logo

Novartis·Phase 2·NCT04268823·54 enrolled

Efficacy1 trial

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

Completed· Novartis logo

Novartis·Phase 2·NCT02449018·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for QBW251. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QBW251 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QBW251. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

QBW251

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Efficacy and Safety1 trial

Bronchiectasis1 trial

Cystic Fibrosis1 trial

Chronic Obstructive Pulmonary Disease1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News